Omeros (NASDAQ:OMER) Receives Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Omeros (NASDAQ:OMER) in a research note issued to investors on Thursday morning,Benzinga reports.

A number of other equities analysts have also recently issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Omeros in a report on Thursday. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Rodman & Renshaw started coverage on Omeros in a research report on Thursday. They issued a “buy” rating and a $9.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $9.00.

Omeros Stock Performance

Shares of NASDAQ:OMER traded down $0.30 during midday trading on Thursday, hitting $6.65. 1,597,222 shares of the stock were exchanged, compared to its average volume of 464,601. The business’s 50-day moving average price is $4.08 and its 200 day moving average price is $4.07. Omeros has a 12 month low of $1.38 and a 12 month high of $7.51. The stock has a market capitalization of $385.35 million, a price-to-earnings ratio of -2.89 and a beta of 1.47.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Omeros by 2.6% in the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after purchasing an additional 81,348 shares during the period. State Street Corp boosted its stake in Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after purchasing an additional 3,839 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Omeros by 4.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after purchasing an additional 18,454 shares during the period. Bank of New York Mellon Corp boosted its stake in Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the period. Finally, Rhumbline Advisers boosted its stake in Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 6,435 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.